Rituximab therapy in autoimmune pulmonary alveolar proteinosis

R Borie; M-P Debray; C Laine; M Aubier; B Crestani

doi:10.1183/09031936.00160908

Rituximab therapy in autoimmune pulmonary alveolar proteinosis

Eur Respir J. 2009 Jun;33(6):1503-6. doi: 10.1183/09031936.00160908.

Authors

R Borie¹, M-P Debray, C Laine, M Aubier, B Crestani

Affiliation

¹ Service de Pneumologie A, Faculté de médecine Denis Diderot, Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Université Paris 7, Paris, France. [email protected]

PMID: 19483052
DOI: 10.1183/09031936.00160908

Abstract

Idiopathic pulmonary alveolar proteinosis is presumed to be an autoimmune disorder that may lead to pulmonary insufficiency. However, steroids do not appear to be effective and the standard of therapy is whole-lung lavage. We report the first case of successful therapy with rituximab, which addresses the pathogenic mechanism of pulmonary alveolar proteinosis.

Publication types

Case Reports

MeSH terms

Adult
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Murine-Derived
Autoimmune Diseases / diagnosis
Autoimmune Diseases / drug therapy*
Biopsy
Bronchoalveolar Lavage
Diagnosis, Differential
Enzyme-Linked Immunosorbent Assay
Humans
Immunologic Factors / therapeutic use*
Pulmonary Alveolar Proteinosis / diagnosis
Pulmonary Alveolar Proteinosis / drug therapy*
Respiratory Function Tests
Rituximab
Tomography, X-Ray Computed

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Murine-Derived
Immunologic Factors
Rituximab